EGFR and non-small cell lung carcinoma: Target-therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), were proven an effective choice for NSCLC patients with EGFR mutations (L858R or deletion in exon 19) [7, 8].